XANTUS programme confirms low bleeding and low stroke rate with Xarelto ® in 11,121 prospectively investigated patients with atrial fibrillation

Results from an analysis of Bayer's XANTUS programme were recently published in the Journal of the American College of Cardiology (JACC)(1). The data confirm the safety profile of the oral Factor Xa inhibitor Xarelto® (rivaroxaban) in routine clinical practice. The analysis highlighted low bleeding and low stroke rates in patients with atrial fibrillation (AF) treated with Xarelto, as well as low rates of treatment discontinuation.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news